3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
145
Kidney Neoplasms
42
Prostatic Neoplasms
16
Neoplasm Metastasis
16
Urinary Bladder Neoplasms
13
Neoplasms
9
Clear-cell metastatic renal cell carcinoma
6
Breast Neoplasms
5
Kidney Diseases
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Urologic Neoplasms
3
Urogenital Neoplasms
3
Urethral Neoplasms
3
Thyroid Neoplasms
3
Ovarian Neoplasms
3
Multiple Myeloma
3
Gastrointestinal Stromal Tumors
3
Carcinoma
3
Stomach Neoplasms
2
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Myeloproliferative Disorders
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Interventions
pazopanib
1
enzalutamide
1
apalutamide
1
Sunitinib
1
Preoperative Exercise
1
Nutritional Support
1
Exercise
1
Ethanol
1
Adiposity
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Patient Preference
×
Sunitinib
×
Genitourinary
×
Clear all
NCT01064310
2017-04-17
PISCES
Novartis
Phase 3
Completed
169 enrolled
16 charts